Literature DB >> 18461151

Ocular toxicity of fludarabine: a purine analog.

Xiaoyan Ding1, Alexandra A Herzlich, Rachel Bishop, Jingsheng Tuo, Chi-Chao Chan.   

Abstract

The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high- and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life- and sight-threatening consequences.

Entities:  

Year:  2008        PMID: 18461151      PMCID: PMC2373270          DOI: 10.1586/17469899.3.1.97

Source DB:  PubMed          Journal:  Expert Rev Ophthalmol        ISSN: 1746-9899


  59 in total

1.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

Authors:  N Di Gaetano; Y Xiao; E Erba; R Bassan; A Rambaldi; J Golay; M Introna
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

2.  Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.

Authors:  D D Von Hoff; S Green; E A Surwit; E V Hannigan; D S Alberts
Journal:  Am J Clin Oncol       Date:  1990-10       Impact factor: 2.339

3.  Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.

Authors:  G R Weiss; J Crowley; D D Von Hoff; S A Taylor; R J Belt; C A Coltman; H E Hynes; J J Costanzi
Journal:  Cancer Treat Rep       Date:  1986-09

Review 4.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Authors:  J M Foran; D Oscier; J Orchard; S A Johnson; M Tighe; M H Cullen; P G de Takats; C Kraus; M Klein; T A Lister
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

Authors:  L Malspeis; M R Grever; A E Staubus; D Young
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

7.  The bioavailability of oral fludarabine phosphate is unaffected by food.

Authors:  D Oscier; J A Orchard; D Culligan; D Cunningham; S Johnson; A Parker; M Klein; H Gieschen
Journal:  Hematol J       Date:  2001

8.  In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.

Authors:  W C Tseng; D Derse; Y C Cheng; R W Brockman; L L Bennett
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

9.  Late listeriosis after fludarabine plus prednisone treatment.

Authors:  C Girmenia; F R Mauro; S Rahimi
Journal:  Br J Haematol       Date:  1994-06       Impact factor: 6.998

10.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

View more
  8 in total

1.  Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.

Authors:  Kyle Jensen; L'Aurelle A Johnson; Pamala A Jacobson; Sonja Kachler; Mark N Kirstein; Jatinder Lamba; Karl-Norbert Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-17       Impact factor: 3.000

2.  Rapid vision loss associated with fludarabine administration.

Authors:  Rachel J Bishop; Xiaoyan Ding; Charles K Heller; Gabor Illei; Rafael C Caruso; Denise Cunningham; Steven Pavletic; Chi-Chao Chan
Journal:  Retina       Date:  2010-09       Impact factor: 4.256

3.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

4.  Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Claudio Annaloro; Antonella Costa; Nicola S Fracchiolla; Gabriella Mometto; Silvia Artuso; Giorgia Saporiti; Elena Tagliaferri; Federica Grifoni; Francesco Onida; Agostino Cortelezzi
Journal:  Clin Case Rep       Date:  2015-06-11

Review 5.  Antiviral Treatment Options for Severe Fever with Thrombocytopenia Syndrome Infections.

Authors:  Yin Zhang; Ying Huang; Yuanhong Xu
Journal:  Infect Dis Ther       Date:  2022-09-22

6.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

7.  Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.

Authors:  John J Krais; Olivier De Crescenzo; Roger G Harrison
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

Review 8.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.